PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112560
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112560
The global liquid handling system market was valued at USD 5.2 billion in 2025 and is projected to reach USD 7.2 billion by 2032, growing at a CAGR of 4.7% between 2026 and 2032. Growth is being driven by the booming life sciences industry and rising investment in developing innovative therapeutic agents, as automated laboratory instruments become essential to drug discovery workflows.
Research funding underpins this demand. The U.S. National Institutes of Health allocated more than USD 47 billion in medical research funding in 2024, supporting biomedical and clinical research activities that rely on precise liquid handling equipment.
Pharmaceutical patent expirations are compelling companies to accelerate drug discovery and early-stage research, driving demand for high-throughput systems, while emerging economies like China and India offer significant growth opportunities through expanding healthcare infrastructure and R&D investment.
Key Insights
Automated systems hold both the largest type share, at 60%, and the highest CAGR, at approximately 5.2%, given demand for high-throughput workflows in pharmaceutical research. Novel drug approvals have increased in recent years, with over 50 approvals reported in several recent cycles, according to the FDA, necessitating automated sample processing.
Pipettes are the largest product category at 35% share, fundamental instruments across research and diagnostic laboratories. Consumables post the highest CAGR, driven by rising usage of disposable tips and cartridges; the NIH Molecular Libraries Program supports high-throughput screening using a shared repository of more than 300,000 chemically diverse compounds.
Drug Discovery is the largest application at 45% share, given extensive pharmaceutical R&D activity. Genomics posts the highest CAGR, at approximately 4.9%, driven by rapid advancements in DNA sequencing and precision medicine adoption.
Biotechnology & Pharmaceutical Companies hold both the largest and fastest-growing end-user share, at 45%, driven by GLP/GMP compliance requirements; the pharmaceutical industry invested approximately EUR 55 billion in R&D across Europe in 2024, according to the European Federation of Pharmaceutical Industries and Associations.
North America holds the largest regional share, at 40%, driven by increasing biotechnology M&A activity. Member companies of the Pharmaceutical Research and Manufacturers of America have invested over USD 1 trillion in R&D since 2000.
Canada is contributing to regional growth too, supported by increasing government funding for life sciences research through agencies like the Canadian Institutes of Health Research.
Asia-Pacific posts the highest regional CAGR, at approximately 5.6%, attributed to rising biotechnology investments. China holds the largest revenue share in the region, supported by the Made in China 2025 strategy prioritizing biopharmaceutical innovation.
India is the fastest-growing country market, driven by government-backed genomic initiatives; the Department of Biotechnology completed the Genome India Project in January 2025, generating whole-genome sequencing data from more than 10,000 individuals across 20 institutions. India's bioeconomy surged from USD 10 billion in 2014 to over USD 130 billion in 2024, according to the Department of Biotechnology.
Rapid integration of automated, high-throughput laboratory systems is a defining trend, as robotics-enabled platforms replace manual processes in drug discovery and genomics. The European Commission's Horizon Europe program has allocated over EUR 95 billion for research and innovation, with a significant portion directed toward life sciences infrastructure.
Rising pharmaceutical and genomics R&D investment remains the biggest driver. Patent expirations affecting more than USD 300 billion in pharmaceutical revenues between 2025 and 2030 are compelling companies to intensify early-stage discovery activity requiring automated infrastructure.
High capital costs and skilled labor deficits are the main restraint. Fully automated liquid handling workstations typically require initial investments ranging from USD 100,000 to over USD 1 million depending on system complexity.
Expansion of emerging market biopharma sectors presents a clear opportunity. Saudi Arabia's National Biotechnology Strategy aims to create 11,000 biotech jobs by 2030 and contribute USD 34.6 billion to non-oil GDP by 2040.
The competitive landscape remains semi-consolidated, dominated by established life sciences companies with proven GLP/GMP-compliant systems and proprietary consumables ecosystems that create switching costs. Recent activity includes Tecan Trading's January 2025 launch of Veya, an AI-enhanced liquid handling platform featuring integrated analytics and remote diagnostics, and Eppendorf AG's April 2025 introduction of new epMotion dispensing tools for qPCR and nucleic acid purification workflows.